The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa

Colleen R. Eade, Amy L. Cole, Camila Diaz, Lisa C. Rohan, Michael A. Parniak, Preston Marx, Patrick Tarwater, Phalguni Gupta, Alexander M. Cole

Research output: Contribution to journalArticle

Abstract

Problem: Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC-101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC-101 on primary vaginal tissues and resident vaginal microflora requires further evaluation. Method of study: We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC-101 to investigate effects of this microbicide. Results: RC-101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC-101. Conclusions: By establishing vaginal microflora, the specific antibacterial activity of RC-101 may provide a dual mechanism of HIV protection. These findings support advancement of RC-101 to clinical trials.

Original languageEnglish (US)
Pages (from-to)150-158
Number of pages9
JournalAmerican Journal of Reproductive Immunology
Volume69
Issue number2
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Anti-Infective Agents
Mucous Membrane
HIV
Bacteria
Heterosexuality
Macaca
RC 101
Cell Culture Techniques
Clinical Trials

Keywords

  • Bacterial Vaginosis
  • Lactobacilli
  • RC-101
  • Theta-defensin
  • Vaginal microbicide

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa. / Eade, Colleen R.; Cole, Amy L.; Diaz, Camila; Rohan, Lisa C.; Parniak, Michael A.; Marx, Preston; Tarwater, Patrick; Gupta, Phalguni; Cole, Alexander M.

In: American Journal of Reproductive Immunology, Vol. 69, No. 2, 01.02.2013, p. 150-158.

Research output: Contribution to journalArticle

Eade, Colleen R. ; Cole, Amy L. ; Diaz, Camila ; Rohan, Lisa C. ; Parniak, Michael A. ; Marx, Preston ; Tarwater, Patrick ; Gupta, Phalguni ; Cole, Alexander M. / The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa. In: American Journal of Reproductive Immunology. 2013 ; Vol. 69, No. 2. pp. 150-158.
@article{0a2791bc2f4d4db3a6de9fa9650eaeaa,
title = "The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa",
abstract = "Problem: Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC-101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC-101 on primary vaginal tissues and resident vaginal microflora requires further evaluation. Method of study: We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC-101 to investigate effects of this microbicide. Results: RC-101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC-101. Conclusions: By establishing vaginal microflora, the specific antibacterial activity of RC-101 may provide a dual mechanism of HIV protection. These findings support advancement of RC-101 to clinical trials.",
keywords = "Bacterial Vaginosis, Lactobacilli, RC-101, Theta-defensin, Vaginal microbicide",
author = "Eade, {Colleen R.} and Cole, {Amy L.} and Camila Diaz and Rohan, {Lisa C.} and Parniak, {Michael A.} and Preston Marx and Patrick Tarwater and Phalguni Gupta and Cole, {Alexander M.}",
year = "2013",
month = "2",
day = "1",
doi = "10.1111/aji.12036",
language = "English (US)",
volume = "69",
pages = "150--158",
journal = "American Journal of Reproductive Immunology and Microbiology",
issn = "1046-7408",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - The Anti-HIV Microbicide Candidate RC-101 Inhibits Pathogenic Vaginal Bacteria Without Harming Endogenous Flora or Mucosa

AU - Eade, Colleen R.

AU - Cole, Amy L.

AU - Diaz, Camila

AU - Rohan, Lisa C.

AU - Parniak, Michael A.

AU - Marx, Preston

AU - Tarwater, Patrick

AU - Gupta, Phalguni

AU - Cole, Alexander M.

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Problem: Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC-101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC-101 on primary vaginal tissues and resident vaginal microflora requires further evaluation. Method of study: We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC-101 to investigate effects of this microbicide. Results: RC-101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC-101. Conclusions: By establishing vaginal microflora, the specific antibacterial activity of RC-101 may provide a dual mechanism of HIV protection. These findings support advancement of RC-101 to clinical trials.

AB - Problem: Vaginal microbicides represent a promising approach for preventing heterosexual HIV transmission. However, preclinical evaluation should be conducted to ensure that microbicides will be safe for human cells and healthy microflora of the female reproductive tract. One microbicide candidate, RC-101, has been effective and well tolerated in preliminary cell culture and macaque models. However, the effect of RC-101 on primary vaginal tissues and resident vaginal microflora requires further evaluation. Method of study: We treated primary vaginal tissues and vaginal bacteria, both pathogenic and commensal, with RC-101 to investigate effects of this microbicide. Results: RC-101 was well tolerated by host tissues, and also by commensal vaginal bacteria. Simultaneously, pathogenic vaginal bacteria, which are known to increase susceptibility to HIV acquisition, were inhibited by RC-101. Conclusions: By establishing vaginal microflora, the specific antibacterial activity of RC-101 may provide a dual mechanism of HIV protection. These findings support advancement of RC-101 to clinical trials.

KW - Bacterial Vaginosis

KW - Lactobacilli

KW - RC-101

KW - Theta-defensin

KW - Vaginal microbicide

UR - http://www.scopus.com/inward/record.url?scp=84872263951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872263951&partnerID=8YFLogxK

U2 - 10.1111/aji.12036

DO - 10.1111/aji.12036

M3 - Article

C2 - 23167830

AN - SCOPUS:84872263951

VL - 69

SP - 150

EP - 158

JO - American Journal of Reproductive Immunology and Microbiology

JF - American Journal of Reproductive Immunology and Microbiology

SN - 1046-7408

IS - 2

ER -